Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
East Bay, Santa Rosa, San Francisco, Solano/Vallejo, San Mateo, Greater Sacramento Valley, Modesto, Palo Alto/Santa Cruz
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer